3 completed. 1 Not applicable, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 1 | Completed 1 |
| Phase 2 | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow MDM S.p.A.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Non-Comparative Study to Assess the Efficacy and Safety of the New Food Supplement FaseMETS Daily administration: 2 tablets FaseMETS a day - Metabolic Syndrome | Not applicable | Completed | MDM S.p.A. | 34 | 2017-05-09 | 2019-10-01 |
| Choline Alphoscerate-Nimodipine in Vascular Cognitive Impairment Choline alphoscerate, Placebo - Vascular Cognitive Impairment | Phase 2 | Completed | Azienda Ospedaliero-Universitaria Careggi | 62 | 2017-05-02 | 2020-01-13 |
| Study to Assess the Efficacy and Safety of Tizaspray® Versus Sirdalud®, in Patients With Acute Low Back Pain Tizaspray® administered intranasally, Sirdalud® 2 mg tablets administered - Low Back Pain | Phase 3 | Completed | MDM S.p.A. | 117 | 2016-10-01 | 2018-01-16 |
Low Back Pain (1) · Metabolic Syndrome (1)
Glycerylphosphorylcholine (1) · tizanidine (1)
Romania (2) · Italy (1)
Antonio Maggi, MD (1) · Doina Rosu, MD (1)
2015 (1)